| 摘要: |
| ［摘要］ 目的 探讨变应性鼻炎（allergic rhinitis，AR）患者经体内螨变应原刺激后T-bet和CD19/CD23的变化。方法 采取15例健康人和60例接受标准化螨变应原疫苗的体内特异性免疫治疗(SIT)达1年的AR患者外周血，用逆转录聚合酶链反应(RT-PCR)分析SIT前后1年外周血单核细胞（PBMC）中的T-bet mRNA表达变化情况。另外用流式细胞术(FCM)检测患者CD19/CD23水平SIT前后1年变化情况。结果 24例AR患者SIT前后PBMC中T-bet表达水平分别为(0.44±0.14)和(0.49±0.09)，差异有统计学意义（t=2.324,P<0.05）。在对照组，该比值为(0.59±0.09)，显著高于AR患者（P<0.01）。对照组和AR组CD19/CD23水平分别是(5.99±2.44)%和(13.53±5.41)%,P<0.05。42例单纯AR患者和合并有哮喘的18例AR患者的T-bet表达水平分别是(0.49±0.12)和(0.33±0.09)，两组CD19/CD23水平分别是(12.32±5.71)%和(16.34±3.32)%,t值分别为5.411和3.407,P均<0.01；T-bet与CD23存在负相关（r=-0.260,P<0.05）。经SIT后，CD23水平显著下降（t=2.334,P<0.05）。经SIT后，T-bet mRNA表达显著上调（t=-2.324,P<0.05）。结论 T-bet在AR患者PBMC中的表达均下调；AR患者经SIT后，可以看到T-bet表达的上调和CD23水平的下降。T-bet对变应原体外反应低下，而对体内小剂量变应原刺激产生保护性的Th1型免疫反应。对变应性鼻炎SIT机理的新认识认为，转录因子水平是通过Th1优势来纠正Th1/Th2失衡，而这种方式是以Th1型特异性相关转录因子的上调表达介导的。 |
| 关键词: 变应性鼻炎 转录因子 变应原 免疫治疗 |
| DOI：10.3969/j.issn.1674-3806.2011.01.03 |
| 分类号:R 765.21 |
| 基金项目:广西卫生厅自筹经费基金项目（编号：Z2007151；Z2008045） |
|
| Response of T-bet expression and CD19/CD23 on peripheral blood in patients with allergic rhinitis after stimulus in vivo by specific standardized allergen |
|
QU Shen-hong, LI Tian-ying, OU Zhi-ying, et al.
|
|
Department of Otolaryngeal,the People′s Hospital of Guangxi Zhuang Autonomous Region,Nanning 530021,China
|
| Abstract: |
| ［Abstract］ Objective To detect the change of T-bet expression and CD19/CD23 on peripheral blood in patients with allergic rhinitis (AR) after specific immunotherapy (SIT).Methods Blood samples were respectively taken from 15 healthy individuals and 60 AR patients who had been accepted SIT in vivo for at least one year. The peripheral blood monouclear cells (PBMC) from two groups was subjected to analysis of T-bet mRNA expression by semiquaitative reverse transcriptase-polymerase chain reaction (RT-PCR).The level of CD19/CD23 was detected by flow cytometry (FCM) before and after SIT.Results The ratio of T-bet to β-actin in 24 AR patients before and after SIT respectively was (0.44±0.14) and (0.49±0.09), between which the difference was statistically significant (t=2.324,P<0.05).In control group, the ratio was (0.59±0.09), which was higher than that in the two above AR group (P<0.01). CD23 (%) in control group and AR group was (5.99±2.44) and (13.53±5.41) (P<0.05). Between 42 AR patients without asthma and other 18 AR patients with asthmatic symptoms, the level of T-bet and CD23 was (0.49±0.12) and (0.33±0.09), (12.32±5.71) and (16.34±3.32), and t value correspondingly and respectively was 5.411 and 3.407, as well as P value correspondingly and respectively was 0.000 and 0.001. T-bet had a negative relation with CD23 (r=-0.260, P=0.045). It indicated significant reduction of CD23 after SIT (t=2.334, P<0.05). T-bet mRNA expression was significantly up-regulated after SIT (χ2=-2.324, P<0.05).Conclusion The download-regulated level of CD23 and up-regulated T-bet expression in peripheral blood of AR patients can be observed after SIT. It develops a new view on SIT of AR that Th1 predominance at the level of transcription factor corrects Th1/Th2 imbalance in this way of mediation of up-regulation of Th1-associated transcription factor. |
| Key words: Allergic rhinitis Transcription factors Allergen Immunotherapy |
